MetLife Investment Management’s Relay Therapeutics RLAY Stock Holding History
Bought
Maintained
Sold
Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
---|---|---|---|---|---|---|---|---|
2025
Q2 | $260K | Buy |
75,117
+9,845
| +15% | +$34.1K | ﹤0.01% | 2040 |
|
2025
Q1 | $171K | Sell |
65,272
-8,894
| -12% | -$23.3K | ﹤0.01% | 2278 |
|
2024
Q4 | $306K | Buy |
74,166
+16,477
| +29% | +$67.9K | ﹤0.01% | 2065 |
|
2024
Q3 | $408K | Hold |
57,689
| – | – | ﹤0.01% | 1891 |
|
2024
Q2 | $376K | Buy |
57,689
+11,636
| +25% | +$75.9K | ﹤0.01% | 1884 |
|
2024
Q1 | $382K | Hold |
46,053
| – | – | ﹤0.01% | 1820 |
|
2023
Q4 | $507K | Hold |
46,053
| – | – | ﹤0.01% | 1677 |
|
2023
Q3 | $387K | Hold |
46,053
| – | – | ﹤0.01% | 1790 |
|
2023
Q2 | $578K | Buy |
46,053
+1,419
| +3% | +$17.8K | ﹤0.01% | 1595 |
|
2023
Q1 | $735K | Hold |
44,634
| – | – | 0.01% | 1406 |
|
2022
Q4 | $667K | Buy |
44,634
+3,817
| +9% | +$57K | 0.01% | 1459 |
|
2022
Q3 | $913K | Buy |
40,817
+2,855
| +8% | +$63.9K | 0.01% | 1238 |
|
2022
Q2 | $636K | Hold |
37,962
| – | – | ﹤0.01% | 1498 |
|
2022
Q1 | $1.14M | Buy |
37,962
+13,536
| +55% | +$405K | 0.01% | 1254 |
|
2021
Q4 | $750K | Buy |
24,426
+3,157
| +15% | +$97K | 0.01% | 1269 |
|
2021
Q3 | $671K | Hold |
21,269
| – | – | 0.01% | 1358 |
|
2021
Q2 | $778K | Buy |
21,269
+3,713
| +21% | +$136K | 0.01% | 1315 |
|
2021
Q1 | $607K | Buy |
17,556
+3,826
| +28% | +$132K | 0.01% | 1412 |
|
2020
Q4 | $571K | Hold |
13,730
| – | – | 0.01% | 1424 |
|
2020
Q3 | $585K | Buy |
+13,730
| New | +$585K | 0.01% | 1287 |
|